Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis
NCT ID: NCT02131051
Last Updated: 2014-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2010-06-30
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis
NCT02131038
Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray
NCT02133053
The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo
NCT01471184
Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents
NCT01342601
Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid
NCT00845195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Azelastine group
Azelastine nasal spray Azelastine eye drops
No interventions assigned to this group
Ectoin group
Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 18-70 years
* Patients with proven allergy and acute symptoms in nose and eye which are treated with Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops or Azelastine Nasal Spray and Azelastine Eye Drops during the observational period
Exclusion Criteria
* drug addicts and persons unable to give consent to study participation,
* patients with intolerance against ingredients of any of the study treatments,
* previous eye or nose surgery,
* concomitant treatment with anti-allergic drugs, and
* diseases which might influence the output of the study according to the physicians' judgment.
* contra indications according to the label
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bitop AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Uwe Sonnemann, MD
Role: PRINCIPAL_INVESTIGATOR
HNO Praxis Elmshorn
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HNO Praxis Elmshorn
Elmshorn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REP-85
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.